2008 · FINDING
Kannengiesser et al. — colitis
Oral KPV reduced macroscopic colitis severity by 60% in rat DSS model.
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
HEALINGRESEARCH
KPV.
The smallest anti-inflammatory peptide worth knowing
AKA · Lys-Pro-Val · α-MSH(11-13)
HEALINGIMMUNEORALSUBCUTANEOUS
The C-terminal tripeptide of α-MSH. KPV carries the anti-inflammatory activity of the full hormone without the pigmentation effects — and it's stable enough for oral delivery.
<1 hour
Half-life
3
Citations
2
Routes
2
Categories
74
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
The C-terminal tripeptide of α-MSH. KPV carries the anti-inflammatory activity of the full hormone without the pigmentation effects — and it's stable enough for oral delivery.
Downregulates inflammation at the cellular level. It enters cells and reduces the NF-κB inflammatory cascade directly — not through any surface receptor.
Often stacked with BPC-157 for gut protocols.
WHAT IT MIGHT HELP WITH.
1
Reduces gut inflammation (colitis models)
2
Downregulates systemic inflammatory markers
3
Oral bioavailability (unlike most peptides)
4
Tissue-healing effects in skin and GI tract
5
Extremely clean safety profile in animal studies
HOW IT WORKS.
§ 02 · MECHANISMDownregulates inflammation at the cellular level. It enters cells and reduces the NF-κB inflammatory cascade directly — not through any surface receptor.
Cell-penetrating tripeptide; acts intracellularly on NF-κB and ERK pathways. Reduces TNF-α, IL-1β, and IL-6 production in macrophages. Distinct from melanocortin receptor signaling.
WHO IT'S FOR
- ✓Gut health research
- ✓Inflammation studies
- ✓Protocols stacking with BPC-157
WHO SHOULD AVOID
- ✕Pregnancy
- ✕Those on immunosuppressants without consultation
THE RESEARCH.
§ 03 · 3 STUDIES2008 · FINDING
Dalmasso et al. — IBD
KPV reduced inflammatory cytokine production in human IBD biopsy cultures.
2000 · FINDING
Cutuli et al. — α-MSH peptides
Landmark work establishing C-terminal tripeptide retains anti-inflammatory activity.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Often stacked with BPC-157 for gut protocols.
500mcg–1mg orally, 1–3x daily (reported range)
FREQUENCY
Most-cited schedule
Multiple times daily due to short half-life
ROUTES
Delivery methods
ORAL · SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
<1 hour
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using KPV should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Oral capsule
- · Subcutaneous vial
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
COMMON STACKS.
§ 05 · COMBINATIONSSIDE EFFECTS & RISKS.
§ 06 · SAFETY·
Mild nausea (oral dosing)
Occasional · mild
·
Injection site reactions
Mild · mild
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for KPV: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on KPV + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.